Catalyst Wire Dossier Catalyst Wire Dossier

agomelatine sublingual tablets

agomelatine · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for agomelatine sublingual tablets, covering 2020-12-23 to 2020-12-24. Get the full timeline:

Most recent: Clinical Trial Update: Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) [Phase 3]

See pricing